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Abstract: The aim of the study was to verify the effects of creatine (Cr) supplementation on functional
capacity (walking capacity; primary outcome) and calf muscle oxygen saturation (StO2) (secondary
outcome) in symptomatic peripheral arterial disease (PAD) patients. Twenty-nine patients, of both
sexes, were randomized (1:1) in a double-blind manner for administration of placebo (PLA, n = 15)
or creatine monohydrate (Cr, n = 14). The supplementation protocol consisted of 20 g/day for 1 week
divided into four equal doses (loading phase), followed by single daily doses of 5 g in the subsequent
7 weeks (maintenance phase). Functional capacity (total walking distance) was assessed by the 6 min
walk test, and calf muscle StO2 was assessed through near infrared spectroscopy. The measurements
were collected before and after loading and after the maintenance phase. The level of significance
was p < 0.05. No significant differences were found for function capacity (total walking distance
(PLA: pre 389 ± 123 m vs. post loading 413 ± 131 m vs. post maintenance 382 ± 99 m; Cr: pre
373 ± 149 m vs. post loading 390 ± 115 m vs. post maintenance 369 ± 115 m, p = 0.170) and the
calf muscle StO2 parameters (p > 0.05). Short- and long-term Cr supplementation does not influence
functional capacity and calf muscle StO2 parameters in patients with symptomatic PAD.
Keywords: intermittent claudication; mobility limitation; dietary supplements
1. Introduction
Walking impairment is the main clinical concern in patients with symptomatic pe-
ripheral artery disease (PAD). In these patients, walking impairment has been associated
with increased barriers to physical activity practice [1], reduced physical activity levels [2],
impaired cardiovascular profile [3,4], increased risk of limb loss, and a higher risk of car-
diovascular disease and mortality [5,6]. Creatine (Cr) is a natural bioenergetic compound,
which is converted to creatine phosphate or phosphocreatine and stored in muscle, where
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it is used for energy production [7]. Previous studies showed that a short period of oral
Cr supplementation increases the amount of Cr available in the muscle by as much as
20% [8] and improves muscle performance in athletes [9] and healthy individuals [10]. In
addition, Cr supplementation promotes improvements in handgrip strength and reduces
lower-limb muscle fatigue [11,12]. In addition, long-term Cr supplementation increased
muscle glycogen content [13,14], leading to an improvement in walking ability in clin-
ical populations [15]. Therefore, as Cr has the ability to increase the muscle content of
both phosphocreatine and glycogen, Cr supplementation could improve walking toler-
ance in patients with PAD, especially after the onset of claudication pain when anaerobic
metabolism becomes predominant. Furthermore, a recent review [16] demonstrated the
potential effects of Cr supplementation on vascular function and the lack of randomized
controlled trials on this topic. Thus, the aim of this study was to analyze the effects of oral
Cr supplementation on functional capacity and calf muscle oxygen saturation (StO2) in
patients with symptomatic PAD.
2. Materials and Methods
2.1. Experimental Design
This was a randomized control pilot trial with a pre-test and post-test design. A 7 day,
double-blind, placebo-controlled study was conducted from December 2016 to October
2017 in São Paulo, Brazil (registered at clinicaltrials.gov as NCT02993874). This manuscript
is reported according to the CONSORT guidelines [17].
Patients were randomly assigned to the experiment in a 1:1 ratio, to blocks of 4–6, con-
sidering sex and total walking distance, to receive either placebo or creatine monohydrate
supplementation according to a computer-generated treatment sequence in a double-blind
design. The randomization process was carried out by a researcher who was not involved
in the project. The primary outcome was total walking distance, as measured by the 6 min
walk test (6MWT). Secondary outcomes were upper-limb strength (handgrip strength test),
lower-limb strength (sit-to-stand test), and calf muscle StO2 assessed by near-infrared
spectroscopy (NIRS). Participants were assessed at baseline (pre intervention), after 1 week
of supplementation (loading), and after 8 weeks (maintenance). Throughout the protocol,
both groups received clinical recommendations for patients with PAD [18].
2.2. Participant Recruitment and Screening
Patients were recruited from a tertiary vascular center in Sao Paulo, Brazil. The sample
consisted of 29 patients of both sexes with PAD and symptoms of intermittent claudication.
The inclusion criteria were the presence of intermittent claudication symptoms during
the 6MWT, ankle brachial index <0.90 in one or both lower limbs, and the absence of
chronic renal insufficiency (creatinine clearance <30 mL/min). Patients were excluded
if they presented any side effects caused by Cr supplementation (i.e., gastric discomfort
or diarrhea) or did not comply with the supplementation procedures. This study was
approved by the Ethics Committee of the Institutions (process 62601416.7.0000.0071). All
patients gave informed consent prior to participation.
2.3. Clinical Characteristics
Demographic information, height, weight, smoking history, and comorbid conditions
(hypertension, dyslipidemia, diabetes, and coronary artery disease) were obtained through
medical history and physical examination. Body mass (kg) and stature (m) were measured
(Welmy, São Paulo, Brazil), and body mass index was calculated. The ankle brachial index
was calculated as the ratio between ankle systolic and brachial systolic blood pressure as
previously described [19]. A trained researcher performed all measurements.
2.4. Creatine Supplementation Protocol and Blinding Procedure
Patients received plain packages containing placebo (PLA) (dextrose) (Probiotica, Sao
Paulo, Brazil) or creatine monohydrate (Cr) supplementation (Creapure, AlzChem Trost-
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berg GmbH, Germany), 20 g/day for 1 week divided into four equal doses (loading phase),
followed by single daily doses of 5 g for the next 7 weeks (maintenance phase). During the
first 7 days (loading phase), supplements were presented in four packages and patients
were instructed to ingest the packages at breakfast, lunch, dinner, and before bedtime.
During the maintenance phase, patients consumed the supplement as a single dose with
their lunch. The supplement packages were coded so that neither the investigators nor the
participants were aware of the contents until completion of the analyses. Quality control
and purity of the Cr were guaranteed by the manufacturer. The supplements were provided
by a staff member of our research team who did not participate in acquisition, analyses,
or interpretation of the data. Adherence to the supplementation was determined in a
subsample of nine patients through plasma creatine levels, using high-performance liquid
chromatography (FL SPD-20A Shimadzu®, Kyoto, Japan), as previously described [20].
Patients in both groups received the recommendation to increase their physical activity
levels as recommended by vascular disease guidelines [18,19]. Physical activity was
monitored using a previously validated pedometer (polar A300, Finland) [21], measured
throughout the 8 weeks of supplementation. Patients were instructed to wear the monitor
while awake and to remove it before bed.
2.5. Primary Outcome—6 Min Walk Test (6MWT)
Patients performed a 6MWT supervised by a trained kinesiologist. Two cones were
placed 30 m apart in a marked corridor as previously described [22]. Patients were in-
structed to walk as many laps around the cones as possible and to report when the claudi-
cation symptom occurred. It is worth mentioning that none of the patients stopped during
the test. The kinesiologist recorded the initial claudication distance (ICD) and total walking
distance (TWD) to evaluate the walking capacity. In PAD patients, the 6MWT presents
high reliability, with the intraclass correlation coefficient ranging between 0.94 and 1.00
and the coefficient of variation ranging between 0.4% and 1.6% [22].
2.6. Secondary Outcomes
Calf Muscle Oxygen Saturation (Calf Muscle StO2)
Calf muscle StO2 was assessed during the 6MWT using near-infrared spectroscopy
(PortaMon, Artinis Medical Systems) through a sensor attached on the leg with the lowest
ankle brachial index. The sensor was attached to the skin on the medial portion of the
gastrocnemius muscle, and several calf muscle StO2 parameters were obtained before,
during, and after the 6MWT (Figure 1). Before the test, a baseline measure of calf muscle
StO2 was obtained at rest (sitting position) for 3 min to allow stabilization of the values
(baseline StO2). During exercise, the minimum calf muscle StO2 value (minimum StO2)
was obtained, as the time taken to reach the minimum value (time to minimum) and the
absolute drop in calf muscle StO2 from rest (baseline StO2) to the minimum exercise value
(minimum StO2). The end of the 6MWT was recorded (completion of test), as well as
the maximal calf StO2 value during recovery (full recovery maximum StO2) in the sitting
position. The recovery times for calf muscle StO2 to reach the full resting value (recovery
phase time) and the maximum calf muscle StO2 value (recovery time to maximum) were
calculated [23].
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Figure 1. Calf muscle oxygen saturation (StO2) parameters obtained before, during, and after the 6 min walk test (6MWT)
test in symptomatic peripheral artery disease (PAD).
2.7. Handgrip Strength Test
Handgrip strength was me sured using a digit l hand dynamometer (Model HE101,
WCT fitness). The measur ment was perfo med with the participant in a sitting position,
with the shoulder adducted in a neutral position and without rotation. The elbow joints
were positioned at 90◦ flexion, with the forearm and wrist in a neutral position. Measure-
ments were performed three times on both arms and the highest value was considered.
2.8. Sit-to-Stand Test
Participants were asked to start by sitting with their feet on the floor and their upper
limbs bent over the chest, and then to stand up a d sit d wn again without using th ir arms.
Participan s repeated the action five times as quickly as possible, and the time required to
c mplete the five repetitions was recorded [24].
2.9. Statistical Analysis
The sample power was calculated using the G* Power software 3.19 statistics program.
Thus, considering that the current sample included 29 patients (PLA, n = 15; Cr, n = 14)
with an effect size of 1.91 and alpha error of 0.05, the sample power was 0.80. The normality
of the data was verified using the Shapiro–Wilk test. The comparison between the general
characteristics of the sample as performed using the t-test for independent samples.
The categorical data were compared using the chi-square test. The baseline values were
assessed using th Mann–Whitney U test. To verify the eff ct of supplementation, the
generalized stimating quation model for repeated measures was p rformed. The level of
sig ificance was p < 0.05.
3. Results
The characteristics of the groups are presented in Table 1. Groups were similar at
baseline in all clinical characteristics (p > 0.05).
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(n = 14) p-Value
Women (%) a 54 46 0.56
Age (years) a 64 ± 8 64 ± 10 0.54
Weight (kg) a 77 ± 10 68 ± 17 0.18
Height (m) a 1.64 ± 0.09 1.60 ± 0.06 0.21
Body mass index (kg/m2) a 28.7 ± 3.1 26.7 ± 6.5 0.43
Ankle-brachial index (mmHg) a 0.50 ± 0.13 0.51 ± 0.16 1.00
Initial claudication distance (m) a 143 ± 84 143 ± 65 0.88
Total walking distance (m) a 371 ± 81 344 ± 82 0.65
Comorbidities (%)
Hypertension b 86.7 78.6 0.67
Diabetes b 60.0 50.0 0.43
Dyslipidemia b 6.7 7.1 0.74
Current smoking b 78.6 78.6 0.68
Coronary artery disease b 46.7 28.6 0.26
Data are presented as the mean and standard deviation for numerical variables and frequency for
categorical variables. a t-Test for independent samples. b Chi-square test. PLA—placebo group;
Cr—creatine group.
Initially, 160 patients were interviewed for eligibility; of these, 118 did not meet the
inclusion criteria, five refused to participate, and five were not included for other reasons
such as not answering phone calls (two subjects), difficulty in traveling because they lived
far away (one patient), and being involved in another study (two patients). Thus, 32 patients
started the study, with 17 allocated to the placebo group and 15 to the Cr group. Before
the beginning of the protocol, one patient was excluded for not attending the evaluation
(placebo; n = 1). During the loading period, one patient receiving Cr was excluded due to
gastric discomfort (n = 1). During the maintenance supplementation period, one patient
was excluded for presenting pleural perfusion (placebo group). Twenty-nine patients
completed the study (PLA, n = 15; Cr, n = 14) (Figure 2).
Patients taking Cr presented higher plasma creatine levels than the placebo group
(PLA: pre 21.5 ± 38.9 µmol/L vs. post 30.7 ± 39.8 µmol/L; Cr: pre 32.1 ± 61.4 µmol/L vs.
post 163.2 ± 42.65 µmol/L; time × intervention effect, p = 0.042).
No significant interactions were found for ICD (Figure 3A) (PLA: pre 124 ± 72 m
vs. post loading 150 ± 199 m vs. post maintenance 145 ± 90 m; Cr: pre 124 ± 73 m vs.
post loading 168 ± 90 m vs. post maintenance 193 ± 110 m; time × intervention effect,
p = 0.532) and TWD (Figure 3B) (PLA: pre 389 ± 123 m vs. post loading 413 ± 131 m vs.
post maintenance 382 ± 99 m; Cr: pre 373 ± 149 m vs. post loading 390 ± 115 m vs. post
maintenance 369 ± 115 m; time × intervention effect, p = 0.170). However, we observed a
significant increase in ICD from pre to post loading in both groups (time effect, p = 0.009).
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Figure 3. Functional capacity parameters obtained during the 6MWT test, handgrip strength test, and sit-to-stand test
before (pre) and after the loading and maintenance supplementation period in symptomatic peripheral arterial disease (n =
29; PLA = 15 and Cr = 14). Data are expressed as the median and interquartile range. * Significant difference pre vs. post
loading supplementation period (p < 0.05). (A) ICD = initial claudication distance; (B) TWD = total walking distance; (C)
sit-to-stand test; (D) handgrip strength test. PLA—placebo group; Cr—creatine group.
For physical activity levels (number of steps), no differences were found at pre vs. post
supplementation (PLA: pre 457 ± 652 steps/day vs. post maintenance 465 ± 602 steps/day;
Cr: pre 584 ± 360 steps/day vs. post maintenance 599 ± 314 steps/day; time effect = 0.258;
time × intervention effect, p = 0.357).
There were no changes in the sit-to-stand test (Figure 3C) (PLA: pre 14.8 ± 2.9 s vs.
post loading 15.1 ± 3.2 s vs. post maintenance 13.6 ± 1.5 s; Cr: pre 14.1 ± 5.1 s vs. post
loading 15.6 ± 5.9 s vs. post maintenance 16.1 ± 2.2 s; time × intervention effect, p = 0.400)
or handgrip strength test (Figure 3D) (PLA: 32.5 ± 16.0 kgf vs. post loading 34.3 ± 15.4 kgf
vs. post maintenance 32.4 ± 13.7 kgf; Cr: pre 28.3 ± 15.2 kgf vs. post loading 29.2 ± 11.7 kgf
vs. post maintenance 29.3 ± 10.2 kgf; time × intervention effect, p = 0.251).
The effects of supplementation on calf muscle StO2 parameters are presented in Table 2.
No significant time × intervention interaction was found for any parameter (p > 0.05).
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Table 2. Calf muscle StO2 data before (pre) and after the short period (post loading) and long period




(n = 14) p-Value Interaction
Baseline StO2 (%)
Pre 68.8 ± 3.7 70.0 ± 4.6
0.082Post loading 68.2 ± 2.8 70.5 ± 6.1
Post maintenance 71.3 ± 5.7 71.1 ± 4.8
Minimum StO2 (%)
Pre 54.2 ± 10.0 61.6 ± 13.0
0.191Post loading 52.9 ± 9.3 61.7 ± 14.8
Post maintenance 54.2 ± 7.7 62.8 ± 12.3
Time to minimum StO2 (s)
Pre 52.5 ± 34.3 56.5 ± 46.1
0.833Post loading 46.8 ± 58.6 44.4 ± 26.2
Post maintenance 50.1 ± 88.3 58.4 ± 43.5
Completion of test (%)
Pre 12.2 ± 8.5 7.2 ± 9.7
0.691Post loading 12.1 ± 8.2 9.5 ± 7.1
Post maintenance 9.2 ± 10.5 7.6 ± 10.4
Recovery time to maximum StO2 (s)
Pre 158.9 ± 43.1 160.1 ± 175.1
0.723Post loading 146.4 ± 75.1 177.1 ± 202.9
Post maintenance 160.9 ± 119.1 181.9 ±125.8
Recovery phase time StO2 (s)
Pre 126.7 ± 112.4 132.9 ± 194.2
0.827Post loading 93.0 ± 77.7 121.1 ± 248.3
Post maintenance 87.1 ± 137.5 130.3 ± 103.7
Full recovery maximum StO2 (%)
Pre 69.5 ± 15.8 72.6 ± 12.4
0.312Post loading 68.6 ± 9.7 72.3 ± 14.5
Post maintenance 74.5 ± 15.8 73.1 ± 15.8
Data are expressed as the median and interquartile range. PLA—placebo group; Cr—creatine group.
4. Discussion
The main findings of this pilot study were that short- and long-term Cr supplemen-
tation did not improve functional capacity and calf muscle StO2 in symptomatic PAD
patients.
Previous studies demonstrated that short- and long-term Cr supplementation in-
creases physical performance in healthy subjects [10,25,26] and in patients with chronic
diseases [15]. In contrast, our findings demonstrate no effects of Cr supplementation on
6MWT in symptomatic PAD patients. A potential explanation is that Cr rapidly increases
the energy stores in type II fibers, and pain during walking in symptomatic PAD occurs
mainly in calf muscles, predominantly composed of type I fibers [27]. Another factor may
be related to the combination of Cr supplementation with other nutritional supplements.
Benedetto et al. [15] analyzed the effects of 8 weeks of Cr supplementation combined
with Coenzyme Q10 on walking capacity (6MWT) in patients with chronic obstructive
pulmonary disease, and they demonstrated a significant increase of 51 m in the Cr supple-
mentation group compared to the placebo group. In fact, Coenzyme Q10 is a compound
that acts on the electron transport chain participating in cell respiration, helping to generate
energy in the form of ATP [28]. As we only used Cr supplementation without the combi-
nation of other nutritional supplements, it is possible that the effects of Cr in the muscle
were attenuated. Thus, future studies are necessary to investigate whether a combination
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of different nutritional supplements can improve physical performance in symptomatic
PAD patients.
We also analyzed the microcirculation during the 6MWT using the calf muscle
StO2 technique. Cr acts on microcirculation due to the increased activity of sensory
nerves and epoxygenase metabolites, particularly epoxyethane diacetic acid, related to
the endothelium-derived hyperpolarization factor [29]. Previous studies showed that Cr
supplementation improved calf muscle StO2 in healthy young people [30] and vegan indi-
viduals [31]. However, in our study, Cr supplementation did not change any calf muscle
StO2 parameters, which agrees with the results of the 6MWT. Thus, these results support
that only Cr supplementation would not be enough to promote changes in microcirculation
and physical performance in symptomatic PAD patients.
In the present study, Cr supplementation did not change other functional capacity
tests, such as the sit-to-stand test and handgrip strength. The positive effects of Cr supple-
mentation in tests involving muscle strength, fatigue, and endurance are controversial. For
example, while Rawson et al. [11] demonstrated that 4 weeks of Cr supplementation re-
duced muscle fatigue assessed with isokinetic dynamometry in healthy older people, Lobo
et al. [32] did not find any adjuvant effect after 1 year of Cr supplementation on lower-limb
strength (sit-and-stand test) in postmenopausal older women. Taken together, these results
suggest that the effects of Cr supplementation on muscle function are influenced by sample
characteristics and methods to assess muscle function.
Our study presents some limitations. Although we analyzed the amount of creatine
in the blood [33], we did not measure the content of creatine in the muscle and, thus,
the impact of supplementation on the calf muscle was not determined. Our findings are
restricted to the time of supplementation and the dosage of creatine used in this study.
Furthermore, a limitation is the small sample size, and more studies are necessary with
larger sample. Other tests to assess muscle function could be used, such as isokinetic
dynamometry and a treadmill. However, we included tests to assess the strength in
upper and lower limbs and the 6MWT, which represent greater clinical relevance in these
patients [34–36]. Lastly, we only analyzed the effects of Cr supplementation for 8 weeks,
and more studies with longer periods of supplementation are necessary.
5. Conclusions
Our results demonstrated that a short period (loading for 1 week) and a long period
(maintenance for 8 weeks) of Cr supplementation do not increase functional capacity
(walking distance, and upper- and lower-limb muscle strength) and calf muscle StO2 in
patients with symptomatic PAD. This pilot study is applicable to the development of new
Cr supplementation strategies to improve the performance and health outcomes in PAD
population.
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